Professor Ma Shaohua from Tsinghua Shenzhen International Graduate School Leads Team to Visit Shenzhen Cell Valley

Recently, Professor Ma Shaohua, Vice Dean of the Institute of Biomedicine and Health Engineering at Tsinghua Shenzhen International Graduate School (SIGS), led a research team to visit Shenzhen Cell Valley. They were received by Professor Wang Jianxun, Chief Scientist of Shenzhen Cell Valley, and Dr. Fu Yuchen, Assistant to the Chairman, who subsequently held a symposium with the visiting delegation.

Accompanied by Dr. Fu Yuchen, the visiting team toured the Smart Exhibition Hall of Shenzhen Cell Valley. Dr. Fu provided a detailed introduction to the valley’s strategic positioning in the Cell and Gene Therapy (CGT) sector, the background of its founding team, core technical routes, advantages in GMP-grade cell product preparation, and its talent cultivation system.

During the symposium, Professor Wang Jianxun extended a warm welcome to the visiting team. Subsequently, Dr. Fu Yuchen systematically outlined the company’s recent progress in early-stage research CRO services, clinical outcome translation, and genetically engineered cell therapies for solid tumors. Professor Wang highlighted that, leveraging the company’s independently developed industrial-grade retroviral vector platform, Shenzhen Cell Valley has successfully produced a series of GMP-grade CAR-T cell products targeting BCMA, CD19, CD19/CD22, CD7, and CD38. The company has established substantive collaborations with over 50 Grade A tertiary hospitals nationwide, cumulatively treating more than 80 patients with hematological malignancies such as multiple myeloma, lymphoma, and leukemia. Furthermore, the company is jointly conducting multi-target and customized CAR-T/CAR-NK research-grade and clinical-grade vector-to-cell full-process services for solid tumors with several hospitals, covering complete stages including Investigator-Initiated Trial (IIT) applications, post-infusion monitoring, and follow-up.

Professor Ma Shaohua introduced the overall profile of the SIGS Institute of Biomedicine and Health Engineering. Established in 2019, the institute is one of the six key thematic areas prioritized by SIGS, focusing on three major research directions: cell engineering, health engineering, and pharmaceutical engineering. It has achieved a series of original results in fields such as tumor organoids, liver and lung fibrosis organoids, and neural organoids. He noted that the institute is advancing a training model that immerses professional master’s and doctoral students in corporate internships and practices. He expressed hope to establish cooperative relationships with Shenzhen Cell Valley in joint talent cultivation, scientific research breakthroughs, and technology translation.

Both parties conducted in-depth discussions on cross-innovation between organoids and cell therapies, joint research projects, and the establishment of graduate internship bases. They reached a consensus to establish a normalized communication mechanism to jointly promote the deep integration of industry, academia, and research.